Compare Abbott Laboratories (ABT) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs J M Smucker Co — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while J M Smucker Co trades at $112.65 (market cap $12.10B). The key difference: Abbott Laboratories is far larger — about 13.8× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| ABT | SJM | |
|---|---|---|
Market Cap | $166.94B | $12.10B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $117.05 |
52-Week Low | $82.57 | $89.53 |
Enterprise Value | $193.69B | $19.13B |
Dividend Yield | 2.63% | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
J.M. Smucker (SJM) trades at $113.24, down 2.61% on the day, with a bullish technical signal from moving averages. The company reported mixed Q4 2026 results, beating EPS estimates but facing sales pressure, with fiscal 2027 revenue guidance projecting a 3-4% decline. Strong cash flow supports a sustainable 4% dividend yield, while valuation metrics show a P/E of 22.05 and P/S of 1.32.
SJM presents a value opportunity with analyst consensus at $122.92 (8.5% upside), but faces headwinds from weak sales visibility and portfolio challenges. The stock's outlook hinges on Uncrustables growth and coffee margin recovery, with balanced risks between dividend stability and competitive pressures in packaged foods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
